20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.18% | 33.34% | 35.45% | 8.20% | 9.08% |
| Total Depreciation and Amortization | -35.65% | -37.18% | -30.22% | -21.54% | -15.04% |
| Total Amortization of Deferred Charges | 14,120.00% | 2,202.00% | 173.02% | -100.00% | -60.94% |
| Total Other Non-Cash Items | -32.63% | -64.31% | -38.69% | 79.12% | 130.56% |
| Change in Net Operating Assets | 0.79% | 32.39% | -20.38% | 53.45% | 23.93% |
| Cash from Operations | -14.93% | 27.01% | 37.70% | 39.90% | 42.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1,619.29% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 1,074.78% | -1.64% | 117.40% | 361.58% | 737.45% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 995.28% | 340.81% | 552.94% | 1,156.90% | 496.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 252.72% | 73.80% | 69.00% | 56.13% | 55.62% |